Patents by Inventor Qingping Zeng

Qingping Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thiadiazole compounds and methods of use
    Publication number: 20080269243
    Abstract: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Application
    Filed: March 19, 2008
    Publication date: October 30, 2008
    Applicant: Amgen Inc.
    Inventors: Holger Monenschein, G. Erich Wohlhieter, Qingping Zeng
  • Thiadiazole compounds and methods of use
    Publication number: 20080255145
    Abstract: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Application
    Filed: March 19, 2008
    Publication date: October 16, 2008
    Applicant: Amgen Inc.
    Inventors: Holger Monenschein, James T. Rider, Guomin Yao, Qingping Zeng
  • Thiadiazole compounds and methods of use
    Patent number: 7354944
    Abstract: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: April 8, 2008
    Assignee: Amgen Inc.
    Inventors: Qingping Zeng, Guomin Yao, George Erich Wohlhieter, Vellarkad N. Viswanadhan, Andrew Tasker, James Thomas Rider, Holger Monenschein, Celia Dominguez, Matthew Paul Bourbeau
  • Thiazole compounds and methods of use
    Publication number: 20070173506
    Abstract: The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Application
    Filed: January 11, 2007
    Publication date: July 26, 2007
    Applicant: AMGEN INC.
    Inventors: Qingping Zeng, John Allen, Matthew Bourbeau, Celia Dominguez, Christopher Fotsch, Nianhe Han, Fang-Tsao Hong, Xin Huang, Matthew Lee, Aiwen Li, Qingyian Liu, James Rider, Seifu Tadesse, Andrew Tasker, Vellarkad Viswanadhan, Xianghong Wang, Kurt Weiler, George Wohlhieter, Guomin Yao, Chester Yuan
  • Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
    Patent number: 7119094
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: October 10, 2006
    Assignee: Warner-Lambert Company
    Inventors: Michael S. South, John J. Parlow, Darin E. Jones, Brenda Case, Tom Dice, Richard Lindmark, Michael J. Hayes, Melvin L. Rueppel, Rick Fenton, Gary W. Franklin, Horng-Chih Huang, Wei Huang, Carrie Kusturin, Scott A. Long, William L. Neumann, David B. Reitz, John I. Trujillo, Ching-Cheng Wang, Rhonda Wood, Qingping Zeng, Matthew W. Mahoney
  • Thiadiazole compounds and methods of use
    Publication number: 20060154961
    Abstract: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
    Type: Application
    Filed: October 18, 2005
    Publication date: July 13, 2006
    Inventors: Qingping Zeng, Guomin Yao, George Wohlhieter, Vellarkad Viswanadhan, Andrew Tasker, James Rider, Holger Monenschein, Celia Dominguez, Matthew Bourbeau
  • Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
    Publication number: 20050165062
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Application
    Filed: December 10, 2004
    Publication date: July 28, 2005
    Applicant: Pharmacia Corporation
    Inventors: Michael South, Qingping Zeng, Ashton Hamme, Melvin Rueppel
  • Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
    Patent number: 6908919
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: June 21, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael S. South, Brenda L. Case, Thomas A. Dice, Ricky L. Fenton, Gary W. Franklin, Michael J. Hayes, Horng-Chih Huang, Wei Huang, Darin E. Jones, Carrie L. Kusturin, Richard J. Lindmark, Scott A. Long, William L. Neumann, David B. Reitz, John I. Trujillo, Ching-Cheng Wang, Rhonda Wood, Qingping Zeng, Matthew W. Mahoney, John J. Parlow, Melvin L. Rueppel
  • Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
    Patent number: 6867217
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: March 15, 2005
    Assignee: Pharmacia Corporation
    Inventors: Michael S. South, Qingping Zeng, Ashton T. Hamme, II, Melvin L. Rueppel
  • Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
    Publication number: 20050043313
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Application
    Filed: September 14, 2004
    Publication date: February 24, 2005
    Inventors: Michael South, Brenda Case, Thomas Dice, Ricky Fenton, Gary Franklin, Michael Hayes, Horng-Chih Huang, Wei Huang, Darin Jones, Carrie Kusturin, Richard Lindmark, Scott Long, William Neumann, David Reitz, John Trujillo, Ching-Cheng Wang, Rhonda Wood, Qingping Zeng, Matthew Mahoney, John Parlow, Melvin Rueppel
  • 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
    Publication number: 20040106626
    Abstract: The present invention relates to compounds, and prodrugs thereof, composition and methods useful for preventing and treating thrombotic conditions in mammals. The compounds of the present invention, and prodrugs thereof, selectively inhibit certain proteases of the coagulation cascade.
    Type: Application
    Filed: October 3, 2002
    Publication date: June 3, 2004
    Applicant: Pharmacia Corporation
    Inventors: Michael S. South, Ronald K. Webber, Horng-Chih Huang, Mihaly V. Toth, Alan E. Moormann, Jeffery S. Snyder, Jeffrey A. Scholten, Danny J. Garland, Melvin L. Rueppel, William L. Neumann, Scott Long, Wei Huang, John Trujillo, John J. Parlow, Darin E. Jones, Brenda Case, Michael J. Hayes, Qingping Zeng, Ricky L. Fenton, Carrie L. Kusturin, Hayat K. Rahman, Zaheer Abbas, Kirby R. Sample, Barbara A. Schweitzer, Rhonda S. Wood, Jim Szalony, Osman D. Suleymanov, Anita Salyers, Nancy S. Nicholson
  • Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
    Publication number: 20040102448
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of dirombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Application
    Filed: October 23, 2003
    Publication date: May 27, 2004
    Applicant: Pharmacia Corporation
    Inventors: Michael S. South, John J. Parlow, Darin E. Jones, Brenda Case, Tom Dice, Richard Lindmark, Michael J. Hayes, Melvin L. Rueppel, Horng-Chih Huang, Wei Huang, Scott A. Long, Matthew W. Mahoney, William L. Neumann, David B. Reitz, John I. Trujillo, Ching-Cheng Wang, Rhonda Wood, Qingping Zeng, Rick Fenton, Gary W. Franklin, Carrie Kusturin
  • Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
    Publication number: 20040082585
    Abstract: The present invention relates to prodrug compounds, compositions and methods useful for preventing and treating thrombotic conditions in mammals. The prodrug compounds of the present invention selectively inhibit certain proteases of the coagulation cascade.
    Type: Application
    Filed: October 3, 2002
    Publication date: April 29, 2004
    Applicant: Pharmacia Corporation
    Inventors: Michael S. South, Ronald K. Webber, Horng-Chih Huang, Mihaly V. Toth, Alan E. Moormann, Jeffery S. Snyder, Jeffrey A. Scholten, Danny J. Garland, Melvin L. Rueppel, William L. Neumann, Scott Long, Wei Huang, John Trujillo, John J. Parlow, Darin E. Jones, Brenda Case, Michael J. Hayes, Qingping Zeng
  • Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
    Publication number: 20040006230
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Application
    Filed: July 15, 2002
    Publication date: January 8, 2004
    Applicant: Pharmacia Corporation
    Inventors: Michael S. South, Brenda L. Case, Thomas A. Dice, Ricky L. Fenton, Gary W. Franklin, Michael J. Hayes, Horng-Chih Huang, Wei Huang, Darin E. Jones, Carrie L. Kusturin, Richard J. Lindmark, Scott A. Long, William L. Neumann, David B. Reitz, John I. Trujillo, Ching-Cheng Wang, Rhonda Wood, Qingping Zeng, Matthew W. Mahoney, John J. Parlow, Melvin L. Rueppel
  • Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
    Patent number: 6664255
    Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: December 16, 2003
    Assignee: Pharmacia Corporation
    Inventors: Michael South, John J. Parlow, Darin E. Jones, Brenda Case, Tom Dice, Richard Lindmark, Michael J. Hayes, Melvin L. Rueppel, Horng-Chih Huang, Wei Huang, Scott A. Long, Matthew Mahoney, William L. Neumann, David Reitz, John I. Trujillo, Ching-Cheng Wang, Rhonda Wood, Qingping Zeng, Rick Fenton, Gary W. Franklin, Carrie Kusturin
  • Synthesis of quinobenzoxazine analogues with topoisomerase II and quadruplex interactions for use as antineoplastic agents
    Patent number: 6528517
    Abstract: The present invention discloses a novel quinobenzoxazine self-assembly complex on DNA and on the topoisomerase II-DNA complex. The related model is used to design a new series of quinobenzoxazines, pyridobenzophenoxazines, pyrridonaphthophenoxazines, and other related compounds that may exhibit anticancer or antibiotic activity. The anticancer activity of these compounds is thought to operate via stabilization of the topoisomerase II-DNA complex and/or interaction with G-quadruplexes, while the antibiotic activity of these compounds derives from their ability to inhibit gyrase, the bacterial type II topoisomerase.
    Type: Grant
    Filed: February 4, 1999
    Date of Patent: March 4, 2003
    Assignee: Board of Regents, The University of Texas System
    Inventors: Laurence H. Hurley, Qingping Zeng, Yan Kwok, Jongsik Gam, Sean M. Kerwin
  • Ion triggered alkylation of biological targets by silyloxy aromatic agents
    Patent number: 5831073
    Abstract: A silyloxy aromatic derivative capable of alkylating a target biological molecule when activated by ionic strength. A sequence directed reagent may be constructed by conjugating a methyl silyloxy aromatic derivative to a hexamethylamino linker attached to either the 5' or 3' terminus of an oligonucleotide. Annealing this modified fragment of DNA to its complementary sequence allows for target modification subsequent to ionic activation. The product of this reaction is a covalent crosslink between the reagent and target strands resulting from an alkylation of DNA by the activated silyloxy aromatic derivative. In a preferred embodiment, a nitrophenyl or bromo group is attached to a methyl group of the silyloxy aromatic derivative. This reagent may be similarly linked to an oligonucleotide probe. Activation of the alkylating agent by an ionic signal (X) which may naturally occur, or may be introduced into the media containing the target molecule, such as by the introduction of a salt (MX).
    Type: Grant
    Filed: February 20, 1996
    Date of Patent: November 3, 1998
    Assignee: The Research Foundation of State University of New York
    Inventors: Steven E. Rokita, Tianhu Li, Qingping Zeng
  • Ion triggered alkylation of biological targets by silyloxy aromatic agents
    Patent number: 5493012
    Abstract: A silyloxy aromatic derivative capable of alkylating a target biological molecule when activated by ionic strength. A sequence directed reagent may be constructed by conjugating a methyl silyloxy aromatic derivative to a hexamethyiamino linker attached to either the 5' or 3' terminus of an oligonucleotide. Annealing this modified fragment of DNA to its complementary sequence allows for target modification subsequent to ionic activation. The product of this reaction is a covalent crosslink between the reagent and target strands resulting from an alkylation of DNA by the activated silyloxy aromatic derivative. In a preferred embodiment, a nitrophenyl or bromo group is attached to a methyl group of the silyloxy aromatic derivative. This reagent may be similarly linked to an oligonucleotide probe. Activation of the alkylating agent by an ionic signal (X) which may naturally occur, or may be introduced into the media containing the target molecule, such as by the introduction of a salt (MX).
    Type: Grant
    Filed: June 2, 1993
    Date of Patent: February 20, 1996
    Assignee: The Research Foundation of State University of New York
    Inventors: Steven E. Rokita, Tianhu Li, Qingping Zeng